BACKGROUND: Measurement of estradiol (E(2)) plays a critical role in the diagnosis and clinical management of reproductive disorders. The challenge for all currently available direct methods for measuring E(2) is to provide accuracy and precision across a wide dynamic range. METHODS: We describe the development and multi-site performance evaluation of a direct E(2) assay on the Architect i2000. Assay performance and method comparisons were performed by testing specimens from men, healthy women with regular menstrual cycles, and post-menopausal women using the Architect assay and isotope dilution, gas chromatography-mass spectrometry (ID/GC-MS). Reference intervals were established by testing prospectively collected daily blood draws from 42 healthy women, 72 postmenopausal women and 101 males. RESULTS: No unexpected cross-reactivity or interference was observed for over 40 compounds tested. Recovery was 100+/-10% in the presence of estrone and estriol. Functional sensitivity (%CV<20%) was <15 pg/ml.(1) The imprecision of the assay was <7.1% (total CV), <2.5%, and <2.3% for control sera containing 45, 190, and 600 pg/ml estradiol, respectively. The assay had a correlation of y=1.033 x+0.3156, r(2)=0.99, n=131 compared to ID/GC-MS. Reference intervals for the current Architect Estradiol assay are reported. CONCLUSIONS: Format changes resulted in dramatic improvement in the performance and accuracy of this direct, fully automated assay. The assay is standardized by ID/GC-MS. The assay is clinically useful for serum concentrations from 15 to >4000 pg/ml.
BACKGROUND: Measurement of estradiol (E(2)) plays a critical role in the diagnosis and clinical management of reproductive disorders. The challenge for all currently available direct methods for measuring E(2) is to provide accuracy and precision across a wide dynamic range. METHODS: We describe the development and multi-site performance evaluation of a direct E(2) assay on the Architect i2000. Assay performance and method comparisons were performed by testing specimens from men, healthy women with regular menstrual cycles, and post-menopausal women using the Architect assay and isotope dilution, gas chromatography-mass spectrometry (ID/GC-MS). Reference intervals were established by testing prospectively collected daily blood draws from 42 healthy women, 72 postmenopausal women and 101 males. RESULTS: No unexpected cross-reactivity or interference was observed for over 40 compounds tested. Recovery was 100+/-10% in the presence of estrone and estriol. Functional sensitivity (%CV<20%) was <15 pg/ml.(1) The imprecision of the assay was <7.1% (total CV), <2.5%, and <2.3% for control sera containing 45, 190, and 600 pg/ml estradiol, respectively. The assay had a correlation of y=1.033 x+0.3156, r(2)=0.99, n=131 compared to ID/GC-MS. Reference intervals for the current Architect Estradiol assay are reported. CONCLUSIONS: Format changes resulted in dramatic improvement in the performance and accuracy of this direct, fully automated assay. The assay is standardized by ID/GC-MS. The assay is clinically useful for serum concentrations from 15 to >4000 pg/ml.
Authors: Margaret F Lippincott; Silvia León; Yee-Ming Chan; Chrysanthi Fergani; Rajae Talbi; I Sadaf Farooqi; Christopher M Jones; Wiebke Arlt; Susan E Stewart; Trevor R Cole; Ei Terasawa; Janet E Hall; Natalie D Shaw; Victor M Navarro; Stephanie Beth Seminara Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Natalie D Shaw; Serene S Srouji; Stephanie N Histed; Kristin E McCurnin; Janet E Hall Journal: J Clin Endocrinol Metab Date: 2009-06-23 Impact factor: 5.958
Authors: N D Shaw; J P Butler; S Nemati; T Kangarloo; M Ghassemi; A Malhotra; J E Hall Journal: J Clin Endocrinol Metab Date: 2014-12-09 Impact factor: 5.958
Authors: Natalie D Shaw; Stephanie B Seminara; Corrine K Welt; Margaret G Au; Lacey Plummer; Virginia A Hughes; Andrew A Dwyer; Kathryn A Martin; Richard Quinton; Veronica Mericq; Paulina M Merino; James F Gusella; William F Crowley; Nelly Pitteloud; Janet E Hall Journal: J Clin Endocrinol Metab Date: 2011-01-05 Impact factor: 5.958
Authors: Andrew W McHill; Elizabeth B Klerman; Bridgette Slater; Tairmae Kangarloo; Piotr W Mankowski; Natalie D Shaw Journal: Sleep Date: 2017-03-01 Impact factor: 5.849
Authors: Bob Z Sun; Tairmae Kangarloo; Judith M Adams; Patrick Sluss; Donald W Chandler; David T Zava; John A McGrath; David M Umbach; Natalie D Shaw Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958
Authors: Bob Z Sun; Tairmae Kangarloo; Judith M Adams; Patrick M Sluss; Corrine K Welt; Donald W Chandler; David T Zava; John A McGrath; David M Umbach; Janet E Hall; Natalie D Shaw Journal: J Clin Endocrinol Metab Date: 2019-02-01 Impact factor: 5.958